Close Menu

Mondobiotech

Navigenics’ lower-priced program to incorporate genetic risk data in patients’ annual medical checkup raises questions as to whether personal genomics firms should be broadly marketing their services to physicians.

Details of the deal are sparse, but the partners said they hope their research will lead to the development of genetic tests that can gauge patients’ predisposition to rare diseases and help target individuals most likely to respond to drugs made by MondoBiotech.

Short Reads: Feb 3, 2009

Premium

Broad Institute, Expression Analysis, Helicos BioSciences, University of Texas at Austin, Applied Biosystems, University of Georgia, ABRF, Genomatix, Illumina, Mondobiotech, 23andMe, Kapa Biosystems

BioArray Briefs: 2009.02.03

Premium

Cancer Research UK, Fluidigm, Fox Chase Cancer Center, BioDiscovery, Mondobiotech, 23andMe

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.

Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.

In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.